NervGen Pharma Corp logo

NervGen Pharma Corp

OTCPK:NGENF (Canada)   Ordinary Shares
$ 1.52 +0.02 (+1.33%) 03:56 PM EST
At Loss
Market Cap:
$ 106.88M
Enterprise V:
$ 97.08M
Volume:
43.27K
Avg Vol (2M):
74.05K
Also Trade In:
Volume:
43.27K
At Loss
Avg Vol (2M):
74.05K

Business Description

Description
NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for treating nerve damage and neurodegenerative diseases. NervGen is testing a new drug called NVG-291 in a Phase 1b/2a clinical trial. The company is developing drugs for treating spinal cord injury, multiple sclerosis, and Alzheimer's disease.
Name Current Vs Industry Vs History
Cash-To-Debt 58.89
Equity-to-Asset -0.15
Debt-to-Equity -0.1
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -2.6
3-Year EPS without NRI Growth Rate 5.8
3-Year FCF Growth Rate 0.5
Name Current Vs Industry Vs History
5-Day RSI 41.75
9-Day RSI 40.93
14-Day RSI 39.32
6-1 Month Momentum % 15
12-1 Month Momentum % 38.79

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.83
Quick Ratio 0.83
Cash Ratio 0.77

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.2
Shareholder Yield % 0.05
Name Current Vs Industry Vs History
ROE % -329.18
ROA % -124.37
ROIC % -201.06
ROC (Joel Greenblatt) % -9075.36
ROCE % -322.23

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -5.84
EV-to-EBITDA -5.87
EV-to-FCF -12.05
Earnings Yield (Greenblatt) % -17.12
FCF Yield % -7.82